switching between glp-1 agonists Frontiers Mapping the effectiveness and risks

8 Future directions The advancement of GLP-1 receptor agonists is progressing towards more refined treatment strategies, with tirzepatide at the forefront of research as a dual GIP/GLP-1 receptor agonist (Nauck and DAlessio 2022)

As research continues, these medications may become an important tool for managing a wide range of conditions, from metabolic and cardiovascular health to neuroinflammation and mast cell disorders

Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials

It is a once-daily subcutaneous injection

Firstly, although we defined our inclusion criteria for anti-diabetic drug-nave patients as those who had not received any antidiabetic medication for at least three months (12 weeks), there might be some heterogeneity